First phase II/III trial to verify the efficacy and safety of trifluridine/tipiracil plus bevacizumab as second-line treatment for patients with metastatic colorectal cancer
Contributors: Yasutoshi Kuboki and Takayuki Yoshino;
Department of Experimental Therapeutics and Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan